Opinion on Pharmaceuticals and Healthcare in Netherlands

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor
06 Feb 2001
CommentWire
CommentWire

Organon: lowest dose contraceptive pill on the market

Published By Datamonitor
15 Jun 2001
CommentWire
CommentWire

Organon: Remeron best for stressed depressives

Published By Datamonitor
09 Aug 2001
CommentWire
CommentWire

CryoCor: competing in cardiac cryoablation

Published By Datamonitor
17 Aug 2001
Expert View
Expert View

Licensing Week - August 16, 2002

Last week's licensing news had a truly global feel, with companies from the US, the UK, mainland Europe and Japan getting in on the action. The week saw deals between; AstraZeneca and Xenogen; Crucell and GenVec; Takeda and Human Genome Sciences; Adolor and Eli Lilly; and Anadys and Roche.

Published By Datamonitor
15 Aug 2002
Expert View
Expert View

Pharmaceutical Licensing Weekly Review: August 19 - 23, 2002

Last week's licensing news featured three of the world's biggest pharmaceutical companies: first GlaxoSmithKline joined Pfizer in an alliance with Argonaut, then Pharmacia joined forces with BattellePharma. Johns Hopkins University also had a busy week beating out deals with Crucell and Correlogic Systems. Finally Amgen and Praecis agreed to terminate their failed relationship.

Published By Datamonitor
23 Aug 2002
CommentWire
CommentWire

AstraZeneca: first market approval for Crestor

Although Crestor will be the first third generation statin to launch in western markets, the drug will not make as significant an impact as Pfizer's Lipitor. Safety-driven delays to Crestor's launch mean that it will be competing in a more mature market, and AstraZeneca will have trouble matching the marketing strength of top players Pfizer and Merck & Co.

Published By Datamonitor
13 Nov 2002
Expert View
Expert View

Statins: can the third generation make an impression?

In November 2002 Crestor, AstraZeneca's third generation statin, received its first approval, marking the arrival of the new "superstatins" and illustrating the new threat to the current market leaders Pfizer and Merck & Co. However, this new generation of dyslipidemia treatments may not be as successful as earlier launched products and may suffer from the maturing nature of the market.

Published By Datamonitor
10 Jan 2003
CommentWire
CommentWire

EULAR: Roche and BMS target RA market

By presenting new data at the rheumatology conference currently being held in Amsterdam, Roche and Bristol-Myers Squibb are hoping to encourage uptake of their recently approved rheumatoid arthritis drugs. Although the data illustrates the addition of valuable new treatment options, an increasingly competitive market is set to limit the impact of Rituxan and Orencia in this indication.

Published By Datamonitor
23 Jun 2006
CommentWire
CommentWire

Crucell: failed vaccine disappoints

Crucell has halted development of Aerugen, its late-stage vaccine candidate for the prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients, following disappointing phase III trial results. Although this is something of a setback for vaccine development within the field of cystic fibrosis, other efforts focusing on ion channel therapy still provide a glimmer of hope.

Published By Datamonitor
19 Jul 2006

« | 1 | 2 | » »|

No help is available.